CRISPR Therapeutics AG (CRSP) Net Cash Flow (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Net Cash Flow data on file, last reported at $72.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 214.5% year-over-year to $72.3 million; the trailing twelve-month figure through Mar 2026 stood at $184.6 million (up 139.09% YoY), and the FY2025 full-year result was $49.2 million, up 153.91% from the prior year.
• Net Cash Flow grew to $72.3 million in Q1 2026, from $61.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $317.9 million in Q1 2024 to a low of -$286.4 million in Q4 2022.
• A 5-year average of -$29.9 million and a median of -$2.6 million in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 461.67% in 2022 and jumped 3243.38% in 2023, its largest moves.
• Tracing CRSP's Net Cash Flow over 5 years: stood at -$286.4 million in 2022, then soared by 51.61% to -$138.6 million in 2023, then soared by 152.44% to $72.7 million in 2024, then slipped by 15.98% to $61.1 million in 2025, then increased by 18.36% to $72.3 million in 2026.
• Business Quant data shows CRSP's Net Cash Flow at $72.3 million in Q1 2026, $61.1 million in Q4 2025, and $92.9 million in Q3 2025.